CRISPR/Cas9-Mediated CCR5 Ablation in Human Hematopoietic Stem/Progenitor Cells Confers HIV-1 Resistance In Vivo

Molecular Therapy : the Journal of the American Society of Gene Therapy
Lei XuHongkui Deng

Abstract

Transplantation of hematopoietic stem cells (HSCs) with a naturally occurring CCR5 mutation confers a loss of detectable HIV-1 in the patient, making ablation of the CCR5 gene in HSCs an ideal therapy for an HIV-1 cure. Although CCR5 disruption has been attempted in CD4+ T cells and hematopoietic stem/progenitor cells (HSPCs), efficient gene editing with high specificity and long-term therapeutic potential remains a major challenge for clinical translation. Here, we established a CRISPR/Cas9 gene editing system in human CD34+ HSPCs and achieved efficient CCR5 ablation evaluated in long-term reconstituted NOD/Prkdcscid/IL-2Rγnull mice. The CCR5 disruption efficiency in our system remained robust in secondary transplanted repopulating hematopoietic cells. More importantly, an HIV-1 resistance effect was observed as indicated by significant reduction of virus titration and enrichment of human CD4+ T cells. Hence, we successfully established a CRISPR/Cas9 mediated CCR5 ablating system in long-term HSCs, which confers HIV-1 resistance in vivo. Our study provides evidence for translating CCR5 gene-edited HSC transplantation for an HIV cure to the clinic.

Citations

Jan 18, 2018·Viruses·Shuliang ChenDeyin Guo
Dec 28, 2017·Viruses·Robert J Scarborough, Anne Gatignol
Apr 13, 2018·Human Gene Therapy·Lijuan YinFei Guo
Dec 8, 2017·Frontiers in Immunology·Daryl Anne Victoria WeatherleySarah L Rowland-Jones
May 22, 2018·Biotechnology & Genetic Engineering Reviews·Guido van MarleM John Gill
Feb 24, 2018·Genome Research·Sojung KimJin-Soo Kim
Jul 4, 2018·AIDS Research and Human Retroviruses·Will DampierBrian Wigdahl
Feb 16, 2018·Human Gene Therapy·Yang YangYuquan Wei
Sep 1, 2017·Human Gene Therapy·Saskia KohlscheenUte Modlich
Apr 5, 2019·Molecular Diagnosis & Therapy·Petros PatsaliCarsten W Lederer
May 23, 2019·Human Genetics·Minyoung Lee, Hyongbum Kim
Nov 12, 2019·Briefings in Functional Genomics·Elena Herrera-CarrilloBen Berkhout
Oct 22, 2019·Anti-cancer Agents in Medicinal Chemistry·Wenlou LiuGuan Jiang
Mar 7, 2020·Stem Cells Translational Medicine·Karim BenabdellahFrancisco Martin
Mar 22, 2020·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·Hua Alexander HanBoon-Seng Soh
Nov 7, 2019·Scientific Reports·Tristan ScottKevin V Morris
May 21, 2020·Briefings in Functional Genomics·Jin-Yu SunXiao-Jie Lu
Nov 27, 2019·Briefings in Functional Genomics·Jinyu SunXiaorong Hu
Jul 10, 2020·AIDS Research and Human Retroviruses·Katherine J SessionsAlexandra L Howell
May 6, 2020·Expert Review of Anti-infective Therapy·Matthew W McCarthy
Sep 23, 2020·Journal of Cellular Physiology·Baohong Zhang
Jan 9, 2019·Frontiers in Microbiology·Alexander G AllenBrian Wigdahl
Jan 10, 2019·3 Biotech·Shengwang Jiang, Qingwu W Shen
Sep 12, 2019·The New England Journal of Medicine·Carl H June
Dec 10, 2019·Science China. Life Sciences·Lu WenZi-Jiang Chen
Feb 9, 2020·Clinical and Translational Medicine·Candice Ashmore-Harris, Gilbert O Fruhwirth
Jun 9, 2020·Clinical Genetics·Roya RamezankhaniCatherine M Verfaillie
May 20, 2020·Frontiers in Immunology·Allan BowenRohan Fernandes
Sep 27, 2020·Genes·Ilayda AtesRenee N Cottle
Oct 6, 2018·Retrovirology·Catalina MéndezAnthony D Kelleher
May 31, 2019·World Journal of Gastroenterology : WJG·Viktor LimanskiyDinesh Vyas
Feb 1, 2018·The CRISPR Journal·Ben J NovakRyan Phelan
Sep 12, 2019·The New England Journal of Medicine·Lei XuHu Chen
Apr 23, 2020·Frontiers in Cellular and Infection Microbiology·Jordan ThomasGeorgios Pollakis
Jun 9, 2020·British Journal of Haematology·Olivier HumbertHans-Peter Kiem
Mar 25, 2019·Bone Marrow Transplantation·Alberto Daniel-MorenoMarkus Mezger
Sep 19, 2019·International Journal of Genomics·Gabriela De Nardi Sanches-da-SilvaFabio Mitsuo Lima

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

CRISPR Ribonucleases Deactivation

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on mechanisms that underlie deactivation of CRISPR ribonucleases. Here is the latest research.

CRISPR (general)

Clustered regularly interspaced short palindromic repeats (CRISPR) are DNA sequences in the genome that are recognized and cleaved by CRISPR-associated proteins (Cas). CRISPR-Cas system enables the editing of genes to create or correct mutations. Discover the latest research on CRISPR here.

CRISPR for Genome Editing

Genome editing technologies enable the editing of genes to create or correct mutations. Clustered regularly interspaced short palindromic repeats (CRISPR) are DNA sequences in the genome that are recognized and cleaved by CRISPR-associated proteins (Cas). Here is the latest research on the use of CRISPR-Cas system in gene editing.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.